|
 The FDA in September authorized a booster dose of Pfizer Inc and
partner BioNTech's two-shot COVID-19 vaccine for those aged 65 and
older and some high-risk Americans.
The regulator's advisory panel has also backed the use of Moderna
Inc and Johnson & Johnson's COVID-19 vaccine booster shots.
The government would not recommend one shot over another, and it
might note that using the same vaccine as a booster when possible is
preferable, the NYT report https://nyti.ms/3vmBRYE said, citing
people familiar with the agency's plans.
The FDA declined to comment on the matter.
[to top of second column] |
 U.S. health officials have been
under pressure to authorize the additional shots
after the White House announced plans in August
for a widespread booster campaign pending
approvals from the FDA and the U.S. Centers for
Disease Control and Prevention.
A study by the National Institutes of Health
last week showed people who got Johnson &
Johnson's COVID-19 vaccine as a first shot had a
stronger immune response when boosted with
vaccines from Pfizer and Moderna.
(Reporting by Amruta Khandekar; Editing by Maju
Samuel)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
